Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

770
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
770
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

603
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
603
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

566
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
566
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

81
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
81

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sarcomere dysfunction as the molecular basis of hypertrophic cardiomyopathy.

Nature reviews. Cardiology·2026
Same author

Differential regulation of β1-dependent voltage shifts and kinetic modulation by an extracellular glutamate in NaV1.6 VSDIV.

The Journal of general physiology·2026
Same author

Distinct effects of disease-associated mutations in the proximal C-linker on negatively cooperative binding of cyclic nucleotides to the human HCN4 channel.

Biochemistry and cell biology = Biochimie et biologie cellulaire·2026
Same author

Organizational Culture in Pediatric Cardiology: Results of a Multinational Exploratory Physician Survey with Implications for Team Performance and Patient Safety.

Pediatric cardiology·2026
Same author

Scope and Outcome of Early Repolarization Syndrome in Unexplained Cardiac Arrest: Insights From the National HiRO Registry.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Epinephrine Challenge: Long-Term Evaluation of Test Performance for the Evaluation of Unexplained Cardiac Arrest and Familial Sudden Death.

JACC. Clinical electrophysiology·2026

Related Experiment Video

Updated: Mar 11, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.9K

Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy.

Thomas M Roston1, Filip Van Petegem, Shubhayan Sanatani

  • 1aDepartment of Medicine, University of British Columbia, Vancouver, British Columbia bDepartment of Medicine, University of Alberta, Edmonton, Alberta cDepartment of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia dChildren's Heart Centre, BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.

Current Opinion in Cardiology
|November 19, 2016
PubMed
Summary

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a complex arrhythmia syndrome. Recent advances focus on genotype-specific therapies targeting RYR2 mutations, with flecainide showing promise beyond traditional beta-blockers.

More Related Videos

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells
13:18

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells

Published on: June 28, 2013

22.2K
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

2.2K

Related Experiment Videos

Last Updated: Mar 11, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.9K
Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells
13:18

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells

Published on: June 28, 2013

22.2K
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

2.2K

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a life-threatening inherited arrhythmia syndrome.
  • Arrhythmias are typically triggered by emotional or physical stress and linked to RYR2 gene mutations.
  • Historically, treatment options were limited, carrying significant risks.

Purpose of the Study:

  • To review recent advancements in understanding CPVT.
  • To discuss challenges and emerging genotype-specific therapeutic strategies for CPVT.
  • To explore novel treatment targets based on RYR2 structure and function.

Main Methods:

  • Review of current literature on CPVT pathophysiology and treatment.
  • Analysis of genotype-phenotype correlations in CPVT patients.
  • Evaluation of emerging therapies including flecainide and gene therapy.

Main Results:

  • CPVT exhibits variable expressivity, challenging the notion of universally high sudden death risk.
  • Flecainide and cardiac denervation show potential by targeting arrhythmia mechanisms.
  • Implantable cardioverter-defibrillators have associated risks and should be used judiciously.
  • Gene therapy shows promise in preclinical models.

Conclusions:

  • Genotype-specific therapies are crucial for managing CPVT.
  • Flecainide offers a promising new treatment avenue for CPVT.
  • Further research into molecular mechanisms is vital for developing preventive strategies against sudden cardiac death in CPVT.